These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 20540654

  • 1. Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease.
    Bassil N, Thaipisuttikul P, Grossberg GT.
    Expert Opin Pharmacother; 2010 Jul; 11(10):1765-71. PubMed ID: 20540654
    [Abstract] [Full Text] [Related]

  • 2. Alzheimer's disease and the glutamate NMDA receptor.
    Doraiswamy PM.
    Psychopharmacol Bull; 2003 Jul; 37(2):41-9. PubMed ID: 14566213
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
    Bullock R.
    Alzheimer Dis Assoc Disord; 2006 Jul; 20(1):23-9. PubMed ID: 16493232
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT, Edwards KR, Zhao Q.
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
    Jones RW, Bayer A, Inglis F, Barker A, Phul R.
    Int J Geriatr Psychiatry; 2007 Mar; 22(3):258-62. PubMed ID: 17243195
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Memantine (Namenda) for moderate to severe Alzheimer's disease.
    Ables AZ.
    Am Fam Physician; 2004 Mar 15; 69(6):1491-2. PubMed ID: 15053415
    [No Abstract] [Full Text] [Related]

  • 15. [The clinical relevance of memantine use].
    Sobów T.
    Psychiatr Pol; 2004 Mar 15; 38(2):321-30. PubMed ID: 15307296
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
    Wilkinson D, Andersen HF.
    Dement Geriatr Cogn Disord; 2007 Mar 15; 24(2):138-45. PubMed ID: 17622761
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors.
    Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, Jia XD, Pejović V, Miller ML, Perhach JL, Graham SM.
    CNS Drugs; 2013 Jun 15; 27(6):469-78. PubMed ID: 23733403
    [Abstract] [Full Text] [Related]

  • 20. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
    Tanović A, Alfaro V.
    Rev Neurol; 2013 Jun 15; 42(10):607-16. PubMed ID: 16703529
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.